India  

Rs 150 per dose not sustainable: Bharat Biotech demands higher price for Covaxin from Centre

Zee News Tuesday, 15 June 2021
Bharat Biotech has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin.
0
shares
ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

ISRO plans to launch satellite GISAT-1 on board a GSLV-F10 rocket on August 12 | Oneindia News [Video]

ISRO plans to launch satellite GISAT-1 on board a GSLV-F10 rocket on August 12 | Oneindia News

The Indian Space Research Organisation is getting back into launch activity at Sriharikota spaceport; Today in the afternoon, three militants were killed in an encounter with security forces in..

Credit: Oneindia     Duration: 02:35Published
Covaxin is 77.8% effective against Covid-19, claims Bharat Biotech: Details | Oneindia News [Video]

Covaxin is 77.8% effective against Covid-19, claims Bharat Biotech: Details | Oneindia News

Covaxin maker Bharat Biotech has claimed that the vaccine is 77.8% effective overall against Covid-19 after analysing results for its phase 3 trials. Bharat Biotech also claimed that Covaxin provides..

Credit: Oneindia     Duration: 02:13Published
Bharat Biotech's Covaxin 77.8 per cent effective in protecting against COVID-19| Oneindia News [Video]

Bharat Biotech's Covaxin 77.8 per cent effective in protecting against COVID-19| Oneindia News

Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 according to data from Phase III trials conducted on 25,800 participants across India. The data was submitted to the..

Credit: Oneindia     Duration: 02:03Published

Related news from verified sources

Rs 150 per dose is not sustainable in long run: Bharat Biotech on Centre's Covaxin price


newKerala.com

SII, Bharat Biotech seek hike in government price for Covid vaccines

Serum Institute of India (SII) and Bharat Biotech (BB) are seeking higher prices for Covid-19 vaccines from the Centre amid concerns that the cost of Covishield...
IndiaTimes